Dynamic Functional Mapping of Alzheimer's Spectrum and HIV-related Brain Dysfunction
Project Number1R01NS141729-01
Contact PI/Project LeaderWILSON, TONY W
Awardee OrganizationFATHER FLANAGAN'S BOYS' HOME
Description
Abstract Text
Project Summary/Abstract
Mild cognitive impairment (MCI) remains a critical problem in patients infected with HIV, but it is also commonly
seen in patients with diabetes, early Alzheimer’s disease (AD), Parkinson’s disease, and many other conditions,
and in its mildest form is also a feature of healthy aging. Over six million Americans are currently living with AD
spectrum conditions (i.e., AD/MCI) and roughly half of patients infected with HIV are cognitively impaired, not to
mention the vast numbers with other etiologies. Thus, there is a clear and immediate need to understand the
neurophysiological basis of these impairments and, in the context of HIV, these needs are central to PAR-24-091,
which calls for innovative approaches to identify how HIV specifically primes the system for cognitive decline.
While the mechanisms that underlie cognitive impairment are poorly understood, many studies have probed the
systems-level brain circuits that appear to play a prominent role. These studies have been largely successful in
identifying the circuits, yet we still have a limited understanding of the physiology and dynamics within these
networks, and the level of specificity to HIV related neuropathology versus cognitive impairment more generally.
Quantifying the neural dynamics in affected circuits is critical, as different oscillatory responses (e.g., theta, alpha,
gamma activity) have been found to code for distinct cognitive faculties, even when they occur in overlapping
regions of the brain. Further, current approaches have generally not probed the dynamics, and have not had the
sensitivity or specificity to reliability distinguish HIV-related pathology from similar conditions and/or healthy
aging. Thus, new tools and approaches are needed. Herein, we use an emerging dynamic functional mapping
method based on next-generation magnetoencephalography (MEG) to quantify oscillatory responses serving
cognitive task performance and spontaneous neural activity during rest in three demographically matched groups
(i.e., cognitively impaired adults with HIV, patients on the AD spectrum, and cognitively normal healthy aging
adults). Our novel dynamic mapping approach uses the latest in MEG instrumentation to provide spectrally
resolved maps with excellent temporal and spatial precision, which we will integrate with high-resolution structural
maps of areal brain architecture based on multimodal parcellation, maps of amyloid PET deposition, and a battery
of domain-specific cognitive assessments. Specifically, we will identify the oscillatory dynamics serving visual
attention and visuo-spatial processing (Aim 1), as well as neural entrainment (Aim 2), and quantify spontaneous
cortical activity at rest (Aim 3). Our overarching hypotheses are that these dynamic neurophysiological maps will
delineate unique pathological features underlying HIV-related cognitive decline relative to that observed in AD
spectrum conditions and healthy aging and predict domain-specific cognitive dysfunction. Importantly, our team
has extensive experience working with these patient populations and developing circuit-level markers of brain
pathology using advanced multimodal neuroimaging.
Public Health Relevance Statement
Project Narrative
Mild cognitive impairment is a defining feature of early Alzheimer’s disease, but it is also associated with many
other conditions such as HIV-infection, where the prevalence rate is much higher than the general population.
Despite this, there is a fundamental lack of scientific knowledge regarding the shared and distinct mechanisms
underlying cognitive impairment in people with HIV, early Alzheimer’s disease, and normal aging adults. The
current project uses a state-of-the-art dynamic functional mapping approach to identify the specific brain circuits
and neural processes that uniquely contribute to cognitive impairment in these different populations.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
073136806
UEI
H1TYS4PK8EC5
Project Start Date
24-September-2024
Project End Date
31-August-2029
Budget Start Date
24-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$788,615
Direct Costs
$486,679
Indirect Costs
$301,936
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$788,615
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS141729-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS141729-01
Patents
No Patents information available for 1R01NS141729-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS141729-01
Clinical Studies
No Clinical Studies information available for 1R01NS141729-01
News and More
Related News Releases
No news release information available for 1R01NS141729-01
History
No Historical information available for 1R01NS141729-01
Similar Projects
No Similar Projects information available for 1R01NS141729-01